Try our beta test site
239 studies found for:    Open Studies | "Macular Degeneration"
Show Display Options
Rank Status Study
21 Recruiting The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)
Condition: Age Related Macular Degeneration
Intervention: Genetic: metagenome
22 Recruiting Cytokeratin 8 Level in Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab
23 Not yet recruiting Transpalpebral Micro Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration
Condition: Age-related Macular Degeneration
Interventions: Device: Nova Oculus™ Micro-current electrical stimulation;   Device: Nova Oculus™ Micro-current electrical stimulation - Sham treatment
24 Recruiting Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Other: No interventions are planned
25 Recruiting Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration
Condition: Age Related Macular Degeneration
Interventions: Device: LT-300 Active (PBM);   Device: LT-300 Inactive (Sham)
26 Recruiting Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
Condition: Age Related Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: Bevacizumab;   Drug: Aflibercept;   Other: Control Group
27 Recruiting An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Elamipretide
28 Recruiting Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: Aflibercept
29 Recruiting Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Interventions: Drug: Squalamine Lactate Ophthalmic Solution, 0.2%;   Drug: Placebo Ophthalmic Solution;   Drug: ranibizumab
30 Recruiting Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: SF0166 Topical Ophthalmic Solution
31 Recruiting Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention:
32 Recruiting Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Clinical-grade Human Embryonic Stem Cells
Condition: Dry Age-related Macular Degeneration
Intervention: Biological: retinal pigment epithelium transplantation
33 Recruiting Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases
Condition: Dry Age-related Macular Degeneration
Intervention: Biological: retinal pigment epithelium transplantation
34 Recruiting Non-exudative Age-related Macular Degeneration
Condition: Non-exudative Age-related Macular Degeneration
Intervention:
35 Recruiting Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
Condition: Neovascular Age-related Macular Degeneration
Intervention: Drug: Ranibizumab
36 Recruiting Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Condition: Age-related Macular Degeneration (AMD)
Intervention: Biological: ranibizumab
37 Recruiting Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Condition: Age- Related Macular Degeneration
Interventions: Drug: Minocycline;   Other: Placebo
38 Recruiting Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Biological: OpRegen
39 Not yet recruiting Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
Condition: Exudative Age Related Macular Degeneration
Intervention: Drug: Ranibizumab Injection [Lucentis]
40 Recruiting Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients
Condition: Macular Degeneration, Senile
Interventions: Device: Color retinography;   Device: Optical coherence tomography;   Device: Fundus autofluorescence imaging

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.